




J.P. Morgan Healthcare Conference Presentation

January 13, 2026

Jay S. Duker, M.D.
President and CEO



Legal Disclaimers

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, are forward-looking statements, including but not limited to statements regarding: our expectations regarding our clinical development and regulatory plans; our belief that DURAVYU™ is on track to be the first-to-market of the current investigational sustained release treatments for wet AMD; our belief that DURAVYU has two potential blockbuster indications; our belief that DURAVYU is the only TKI in development for DME; our belief that DURAVYU is uniquely positioned to potentially address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME as a sustained delivery therapy; our belief that DURAVYU's potential real-world application in multiple retinal disease indications and de-risked trial designs position DURAVYU for clinical and commercial success; our expectations regarding timing for commencement of DME clinical trial enrollment and the timing of the availability and release of wet AMD clinical data; our expected cash runway; our belief that DURAVYU has the potential to maintain a majority of patients with active disease with no supplemental anti-VEGF therapy for six months or longer; our expectations regarding our manufacturing capabilities; and our expectations regarding the timing and clinical development of our other product candidates, including EYP-2301. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint's actual results to be materially different than those expressed in or implied by EyePoint's forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the company's clinical development activities, including DURAVYU; uncertainties and delays relating to communications with the U.S. Food and Drug Administration and the ability to obtain regulatory approval from FDA for the commercialization of DURAVYU; unanticipated costs and expenses; the Company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the Company's product candidates; changes in the regulatory environment; disruptions at the FDA, including due to a reduction in the FDA's workforce and/or inadequate funding for the FDA; the impact of the government shutdown on our business operations; changes in U.S. and international trade policies; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates; the availability of and the need for additional financing; our ability to obtain additional funding to support our clinical development programs; uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts; uncertainties regarding the FDA warning letter pertaining to our Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission (SEC). More detailed information on these and additional factors that could affect our actual results are described in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by our Quarterly Reports on Form 10-Q and other documents filed with the SEC. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

A Leader in Sustained Release Drug Delivery for Retinal Disease



DURAVYU™ Phase 3 trials in wet AMD fully enrolled - topline data anticipated in mid-2026



DURAVYU™ Phase 3 DME program underway with FPI expected in Q1 2026



Durasert® IVT delivery brings strong safety profile across multiple FDA approved products and indications



Veteran leadership team with 3+ decades of expertise across clinical drug development, commercialization and manufacturing



Commercial manufacturing scale-up underway in state-of-art MA, USA facility



~\$300M¹ in cash and investments supports runway into Q4 2027

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for DURAVYU. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. These data are preliminary. Conclusive evidence of efficacy and safety of DURAVYU will require further investigation in well-controlled Phase 3 clinical trials.

1. As of December 31, 2025. Unaudited estimate.
AMD, age-related macular degeneration; DME, diabetic macular edema; FPI, first patient in; IVT, intravitreal

DURAVYU™ in Phase 3 Trials For the Two Largest Retinal Disease Markets


Durasert E™ Programs	Indication	Discovery	Pre-Clin	Phase 1	Phase 2	Phase 3	Anticipated Milestone
DURAVYU™ (vorolanib intravitreal insert f/k/a EYP-1901)	Wet AMD	LUGANO and LUCIA fully enrolled					LUGANO topline data in mid-2026
	DME	Phase 3 Pivotal program initiated					FPI in Q1 2026
EYP-2301 (razuprotafib intravitreal insert) (TIE-2 agonist)	Retinal diseases	[Progress bar]					Tox and PK data in 2026

Wet AMD and DME represent a combined \$15B+ global market opportunity and >80% of the total branded retinal market

AMD, wet age-related macular degeneration; DME, diabetic macular edema; FPI, first patient in; PK, pharmacokinetics

Products Addressing Unmet Needs in Retinal Disease Capture Meaningful Market Share in \$15B Anti-VEGF Market

Total Global Branded Anti-VEGF Sales¹



Modest improvements in **durability** and **disease control** are rewarded by the market



~30 days² Durability

\$1.8B Year 3 Sales



~44 days³ Durability

\$3.3B Year 3 Sales



~57 days³ Durability

\$4.3B Year 3 Sales

1. Publicly reported sales; 2. Lucentis package insert; 3. Khanani et. al, The Real-World Efficacy and Safety of Faricimab in Neovascular Age Related Macular Degeneration: TRUCKEE Study – 2 Year Results VEGF, vascular endothelial growth factor.

Longer Duration AND New MOA are Key Unmet Needs in Retinal Disease in 2026

THE UNMET NEEDS

1 Effective, durable disease control

Many patients still lose vision despite available therapies


2 Suppression of inflammation via IL-6

VEGF suppression is not the entire story



THE SOLUTION

DURAVYU




Provides sustained drug release for **≥6 months** with vorolanib, a **multi-MOA** TKI

Vorolanib Features a Novel Multi-MOA, Addressing Both Vascular Leakage and Inflammation

VEGFRs and **PDGFR** play a prominent role in angiogenesis

IL-6 signaling is pro-inflammatory, and promotes vascular leakage and neovascularization





Data on file. Bakri SJ, et al. *PLoS One*. 2024;19(6):e0304782.

IL-6 (R), interleukin 6 (receptor); JAK, janus kinase; MOA, mechanism of action; PDGF(R), platelet-derived growth factor (receptor); PLGF, placental growth factor; TKI, tyrosine kinase inhibitor; VEGF(R), vascular endothelial growth factor (receptor).

Durasert E™: The Next Generation in Sustained-Release Intravitreal Drug Delivery

Over 3 decades of innovation in sustained-release drug delivery

Technology with proven safety in thousands of eyes across 4 FDA-approved products




Insert not drawn to scale, for illustrative purposes only. a Vitrasert now discontinued. 1. Wykoff CC, et al. J Vitreoretin Dis. 2024;8(5):577–86. 2. Bausch and Lomb (2025). RETISERT (fluocinolone acetonide intravitreal implant). [Available at: [Prescribing Information - RETISERT](#)]. 3. Alimera Sciences (2016). ILUVIEN® (fluocinolone acetonide intravitreal implant). [Available at: [Prescribing Information - ILUVIEN](#)]. 4. Alimera Sciences (2023). YUTIQ® (fluocinolone acetonide intravitreal implant). [Available at: [Prescribing Information - YUTIQ](#)]. 5. Patel S, et al. Ophthalmol Sci. 2024;4(5):100527.

IVT, intravitreal; ClinicalTrials.gov identifiers: DAVIO NCT04747197; DAVIO 2 NCT05381948; PAVIA NCT05383209; VERONA NCT06099184; LUGANO NCT06668064; LUCIA NCT06683742.

© 2026 EyePoint. All Rights Reserved.

DURAVYU™ (vorolanib in bioerodible Durasert E™): Best-in-Class TKI for Retinal Disease

DURAVYU™ Bioerodible Insert



Each IVT insert is:
94% drug / 6% matrix
1/5000th of vitreous volume
No PEG/PLGA

- **Novel Multi-MOA**
Inhibition of VEGF receptors, PDGF and pro-inflammatory IL-6–mediated signaling
- **Immediate**
Therapeutic levels of vorolanib reached within hours^{1,a}
- **Sustained**
Consistent daily dosing with target inhibition for ≥6 months
- **Controlled**
Full elution of vorolanib before matrix bioerosion; no free-floating drug particles
- **Convenient**
No cold storage required; pre-loaded IVT syringe injector

Insert not drawn to scale, for illustrative purposes only.

a. Data from preclinical studies. Following a single DURAVYU 900 µg dose in Dutch-Belted rabbits, vorolanib reached concentrations exceeding IC50 in the choroid and retina within hours of administration. 1. Wykoff CC, et al. J Vitreoretin Dis. 2024;8(5):577–86.

TKI, tyrosine kinase inhibitor; MOA, mechanism of action; VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor; IL-6, interleukin 6; IVT, intravitreal; PEG, polyethylene glycol; PLGA, polylactic-co-glycolic acid.

Among All Sustained Delivery Programs in Retinal Disease, **Only DURAVYU** Brings a Novel Multi-MOA *with* 6-month Durability

	DURAVYU¹	OTX-TKI ²	ABBV-RGX-314 ³	ADVM-022 ⁴	4D-150 ⁵	Tarcocimab tedromer ⁶	KSI-501 ⁶	Port delivery system (ranibizumab ⁷)
VEGF Inhibition	✓	✓	✓	✓	✓	✓	✓	✓
IL-6 Inhibition	✓	✗	✗	✗	✗	✗	✓	✗
PDGF Inhibition	✓	✓	✗	✗	✗	✗	✗	✗
≥6 Month Durability	✓	✓	✓	✓	✓	✓	✗	✓
Re-dosing*	✓	?	✗	✗	✗	✓	✓	✓
Office Administration	✓	✓	✗	✓	✓	✓	✓	✗

*Based on Phase 3 trial design and potential label upon approval

1. EyePoint Corporate Presentation October 2025 [[Available online](#)]. Accessed December 11, 2025. 2. Ocular Therapeutix Investor Day Presentation September 2025. [[Available online](#)]. Accessed December 11, 2025. 3. RegenXbio Corporate Presentation September 2025. [[Available online](#)]. Accessed September 29, 2025. 4. Adverum Corporate Presentation August 2025 [[Available online](#)]. Accessed September 29, 2025. 5. 4DMT Corporate Presentation November 2025. [[Available online](#)]. Accessed December 11, 2025. 6. Kodiak Corporate Presentation November 2025. [[Available online](#)]. Accessed December 11, 2025. 7. Regillo C et al. *Ophthalmology*. 2023;130:735-747. MOA, mechanism of action; VEGF, vascular endothelial growth factor; IL-6, interleukin-6; PDGF, platelet-derived growth factor.

DURAVYU Has Demonstrated Robust Efficacy Outcomes and a Positive Safety Profile Across Multiple Indications

Strong safety profile in >190 patients to date across four clinical trials, with no DURAVYU related ocular or systemic SAEs

17 patients received DURAVYU	DAVIO Phase 1 Wet AMD	<ul style="list-style-type: none">Stable vision and OCT with 74% reduction in treatment burden
102 patients received DURAVYU	DAVIO 2 Phase 2 Wet AMD	<ul style="list-style-type: none">Stable vision & strong anatomical control with >80% reduction in treatment burden
51 patients received DURAVYU	PAVIA Phase 2 NPDR	<ul style="list-style-type: none">Prevented worsening of disease severity
21 patients received DURAVYU	VERONA Phase 2 DME	<ul style="list-style-type: none">Rapid & sustained improvements in vision and anatomical control with fewer injections



Based on interim Phase 3 LUGANO/LUCIA masked safety data, the observed **safety profile is consistent** with previous DURAVYU clinical trials

(no safety signals observed)¹

1. EyePoint. Press release November 19, 2025: EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration [Available online]. ClinicalTrials.gov identifiers: DAVIO NCT04747197; DAVIO 2 NCT05381948; PAVIA NCT05383209; VERONA NCT06099184. Data on file. SAE, severe adverse event; AMD, age-related macular degeneration; OCT, optical coherence tomography; NPDR, nonproliferative diabetic retinopathy; DME, diabetic macular edema



DURAVYU for Wet AMD

**POSITIONED TO BE FIRST TO MARKET AMONG ALL
INVESTIGATIONAL SUSTAINED DELIVERY THERAPIES
WITH A BEST-IN-CLASS PROFILE**

LUGANO and LUCIA: Clinically Rigorous, De-risked Phase 3 Wet AMD Program Following Established Non-Inferiority Regulatory Path

Key Elements of Phase 3 Trial Design:

- Informed by the **Phase 1 'DAVIO'** and **large Phase 2 'DAVIO 2'** trials
- **Developed in alignment** with the FDA and EMA
- **Patient-centric design**; all patients receive active treatment with goal of **maintaining or improving vision**
- Key secondary endpoint evaluating **statistical superiority** in **reduction in treatment burden** vs. on-label aflibercept
- **First pivotal program evaluating redosing** of sustained release TKI

LUGANO & LUCIA


Both trials fully enrolled at industry-leading pace

Topline 56-week data expected for LUGANO mid-2026; LUCIA anticipated shortly after

Phase 3 Pivotal Trials in Wet AMD: Trial Design Following an Established Non-Inferiority Regulatory Pathway

LUGANO
&
LUCIA

**Pivotal Phase 3
Trials of Repeat-
Dose DURAVYU
vs On-Label
Aflibercept**



Primary endpoint

Difference in mean change in BCVA from Day 1 to W52 and W56 (blended) vs aflibercept control

Secondary endpoints

- Safety
- Reduction in treatment burden (superiority vs on-label aflibercept)
- Percent of eyes supplement-free
- Anatomical stability

DURAVYU dosing consists of 2 inserts delivered in a single injection.
AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; D, day; W, week; EOS, end-of-study; q6M, every 6 months; q8W, every 8 weeks; R, randomization; SD-OCT, spectral domain optical coherence tomography;

© 2026 EyePoint. All Rights Reserved.

DURAVYU Phase 3 Trials in Wet AMD Supported by DAVIO 2 Results: All Primary and Secondary Endpoints Were Achieved

DAVIO 2 Endpoints in Wet AMD*	2mg	3mg
✓ Primary: Statistically significant non-inferior change in BCVA vs. aflibercept	- 0.3 letters	- 0.4 letters
✓ Secondary: Change in BCVA vs. baseline	+1.0 letters	+0.9 letters
✓ Secondary: Reduction in treatment burden vs. 6 mos. prior	89%	85%
✓ Secondary: Reduction in treatment burden vs. aflibercept	82%	76%
✓ Secondary: Supplement-free up to 6 months	63% 88% of eyes had 0 or 1 supplemental injections	63% 83% of eyes had 0 or 1 supplemental injections
✓ Secondary: Anatomical control vs. aflibercept	+12.4um	+5.2um
✓ Secondary: Favorable safety profile	No DURAVYU-related SAEs	

*DAVIO 2 population entered trial requiring more frequent annual injections (10) than the average US wet AMD patient (6)¹


Note: 6 month timing is post-DURAVYU dosing (8 months of data)

1. NIH Current and Upcoming Anti-VEGF Therapies and Dosing Strategies for the treatment of neovascular AMD: a comparative review, Saira Khanna et al, Dec. 2019. AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; SAE, severe adverse event

DURAVYU in Wet AMD:

Subgroup analysis of DAVIO 2 patients eligible for Phase 3 demonstrates favorable outcomes adding confidence to the Phase 3 plan


BCVA Change from Baseline, Phase 3 Eligible Patients



DAVIO 2 Total Pt. Population

2mg: +1.0
3mg: +0.9

CST Change from Baseline, Phase 3 Eligible Patients



DAVIO 2 Total Pt. Population


2mg: +17.8 um
3mg: +10.6 um

—●— DURAVYU 2mg (n=29) —●— DURAVYU 3mg (n=31) —●— aflibercept 2mg (n=32)

Data on file. Data includes patients in DAVIO 2 with baseline BCVA of 35-78 letters.
BCVA, best-corrected visual acuity; CST, central subfield thickness; ETRDS, Early Treatment of Diabetic Retinopathy Study

DURAVYU in Wet AMD:

Significantly lower supplemental injection rate in DAVIO 2 when applying stricter Phase 3 supplement criteria



Outcomes from this analysis builds confidence in Phase 3 Pivotal program

New Commercial Manufacturing Facility to Support DURAVYU Through Potential NDA Approval and Commercial Launch



41,000sf dedicated facility



USA based in Northbridge, MA



Built to EYPT specifications by landlord preserving upfront cash investment



Built to US FDA and EU EMA standards



DURAVYU registration batches underway to support anticipated NDA filing





DURAVYU for DME

ONLY TKI IN DEVELOPMENT FOR DME WITH PHASE 3 PROGRAM UNDERWAY

COMO and CAPRI: Phase 3 DME Program Designed to Drive Global Regulatory and Commercial Success

Key Elements of Phase 3 Trial Design:

- Informed by **positive Phase 2 VERONA trial**
- Aligned with the FDA and EMA on the pivotal program; **established non-inferiority regulatory path**
- **Leverages existing clinical trial infrastructure** from LUGANO/LUCIA
- **High physician enthusiasm** already observed
- With ~240 patients each, trials are **meaningfully smaller** than wet AMD program, enabling **efficient execution and path to market**

COMO & CAPRI


Global, randomized, double-masked, aflibercept controlled

Identical non-inferiority trials vs. on-label aflibercept

FPI anticipated Q1 2026

Phase 3 Pivotal Trials in DME: Designed to Evaluate Non-Inferiority of DURAVYU vs On-Label Aflibercept Control

COMO
&
CAPRI



Primary endpoint

Difference in mean change in BCVA from Day 1 to W52 and W56 (blended) vs aflibercept control


Secondary endpoints

- Safety
- Reduction in treatment burden (superiority vs on-label aflibercept)
- Percent of eyes supplement-free
- Anatomical stability


DURAVYU dosing consists of 2 inserts delivered in a single injection. 1. Criteria for supplemental injection assessed starting after Week 16 and at every subsequent visit. D, day; W, week. EOS, end of study; q8W, every 8 weeks; R, randomization; DME, diabetic macular edema; BCVA, best-corrected visual acuity

Single DURAVYU 2.7mg Treatment Demonstrated Meaningful Vision and Anatomical Improvement as Early as Week 4

BCVA Change from Baseline



CST Change from Baseline




Single dose on Day 1

*Data excludes one outlier patient. Outlier patient was removed from analysis because the patient missed multiple visits including the Week 20 visit resulting in vision loss of >20 letters at the Week 24 visit. BCVA, best-corrected visual acuity; CST, central subfield thickness; ETRDS, Early Treatment Diabetic Retinopathy Study; VERONA Clinicaltrials.gov Identifier: NCT06099184. Data on file.

DURAVYU 2.7mg in Supplement-Free Eyes Achieved Similar BCVA as Anti-VEGF + Anti-IL-6 Dosed Monthly

BCVA: VERONA DME results superimposed on BARDENAS Phase 2 Trial of anti-IL6 (vamikibart)




BARDENAS Phase 2 clinical trial results adapted from Roche's Pharma Day presentation, September 22, 2025 [Available Online]. Data depicted represent adjusted mean change from baseline in BCVA with 95% confidence intervals. Data points are slightly offset to distinguish error bars. Primary endpoint at Week 44/48, averaged. In VERONA, supplement-free is defined as patients who did not receive a supplement at any point during the study. VERONA Clinicaltrials.gov Identifier: NCT06099184. Data on file. BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; Q4W, every 4 weeks; VA, visual acuity; Wk, week.


Dose-Dependent Reduction in Macular Leakage Area with a Single DURAVYU Injection in DME

Macular leakage is a biomarker of vascular instability in DME

Vascular Leakage Area Change from Baseline to Week 24¹








Case: DURAVYU 2.7 mg Treatment




Marked reduction in leakage area at Week 24 after a single DURAVYU 2.7 mg dose and no supplementation

1. Change from baseline in vascular leakage (mm²) in the macula and in the total retinal area. Full analysis set. DME, diabetic macular edema. VERONA Clinicaltrials.gov Identifier: NCT06099184. Data on file.

Continued Drying at Week 24 with Improved BCVA After a Single DURAVYU 2.7mg Dose and No Supplementation




Anti-VEGF Injections Before and After Treatment



Patient presented with fluid at Screening and Day 1

Fluid dried after a single dose of DURAVYU

Vision improved by +8 letters



BCVA, best-corrected visual acuity; CST, central subfield thickness; D, day; VA, visual acuity; VEGF, vascular endothelial growth factor. VERONA Clinicaltrials.gov Identifier: NCT06099184. Data on file.

DURAVYU™: Potential to be the First and Best in Class TKI in Largest Retinal Indications

Only DURAVYU features a **novel, multi-MOA** with 6-month durability

Robust Phase 1 and 2 efficacy data across wet AMD and DME

Favorable safety and tolerability with **no safety signals** across **four clinical trials**

Topline data for LUGANO/LUCIA Phase 3 trials in wet AMD **expected mid-2026**

Noninferiority Phase 3 DME program underway; **FPI expected in Q1 2026**



J.P. Morgan Healthcare Conference Presentation

January 13, 2026

Jay S. Duker, M.D.
President and CEO

